事件：公司发布2024 年度报告，营收91.1 亿元，yoy+16.5%；归母净利20.9 亿元，yoy+34.9%；经调整净利23.2 亿元，yoy+18.8%。经调利润超预期。基本盘稳定，特比澳顺利续约，2025 有增量：（1）青少年儿童ITP 适应症2024M4获批；（2）慢性肝病适应症24M8 递交NDA。近上市管线将兑现：（1）License in 产品柏瑞素（口服紫杉醇）胃癌已获批上市...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.